This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Is AstraZeneca Worth More Than $106B? Doubtful: StockTwits

NEW YORK (TheStreet) -- AstraZeneca  (AZN) thinks its worth more than $106 billion. But many investors on StockTwits.com don't agree. And they say AstraZeneca's quick rejection of Pfizer's (PFE) sweetened offer for the company could kill chances of a deal.

Not seen it yet, but expecting the headline 'is AstraZeneca deal about to pfizzle away?' $PFE $STUDY -- Tony Parker (@toknees) May. 2 at 07:40 AM

Shares of the pharmaceutical company opened half-a-percent lower Friday after management rejected Pfizer's improved $84.47-per-share bid for the company.

In a press release this morning, AstraZeneca Chairman Leif Johansson said that the deal, worth just over $106 billion, undervalues the company's drug pipeline.

"As such, the Board has no hesitation in rejecting the Proposal," Leif said.

Investors are concerned that Pfizer will drop its pursuit of the company rather than return with a higher offer. The new $84-per-share offer is 10% higher than Pfizer's prior $76.62 offer.

$AZN http://stks.co/g0ZJA says not to $PFE. $AZN shareholders could take a beating if $PFE walks away. Will they? Or go hostile? -- Shiv Kapoor (@shiv139) May. 2 at 08:49 AM

Should Pfizer drop its acquisition bid, many investors who purchased AstraZeneca shares in anticipation of a deal would be left with stock trading at a higher multiple than the market was willing to support sans acquirer interest. AstraZeneca shares are up 18% since Pfizer confirmed its renewed pursuit of the company last week.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,977.01 +16.44 0.10%
S&P 500 1,979.54 +1.20 0.06%
NASDAQ 4,448.0530 -1.5110 -0.03%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs